Final results for the year ended 31 December 2019

April 14, 2020

The Company is pleased to announce its audited results for the year ended 31 December 2019.

Dr. Ian Pike, Interim Chief Executive Officer of Proteome Sciences plc, commented:

“In 2019 we moved into profit as a result of strong growth in both TMT® and biomarker services. TMT® performance was particularly impressive with a 34% growth in underlying revenues and accelerated attainment of a second sales milestone of £0.75m.

View PDF Version

« Back To News